StudiedinpreviouslyuntreatedDLBCLandfollicularlymphoma
Nearly 8 in 10 Patients Preferred RITUXAN HYCELA ®
Administration vs RITUXAN ® (rituximab)
77% of patients preferred subcutaneous administration of RITUXAN HYCELA—
the most common reason cited by patients was less time in the clinic. 1, *
*Actual clinic time may vary. See the PrefMab Trial details on the following pages.
IMPORTANTSAFETYINFORMATION(CONT ’D)
ê Premedicate patients with an antihistamine and acetaminophen (also consider glucocorticoids) prior to each administration of
RITUXANHYCELA.Observepatientsforatleast15minutesfollowingRITUXANHYCELA.Alongerperiodmaybeappropriatein
patients with an increased risk of hypersensitivity reactions
Local Cutaneous Reactions
ê Local cutaneous reactions, including injection site reactions, have been reported in patients receiving RITUXAN HYCELA. Some local
cutaneous reactions occurred more than 24 hours after RITUXAN HYCELA administration
Tumor Lysis Syndrome (TLS)
ê TLScanoccurwithin12–24hoursafteradministrationofarituximab-containingproduct,includingRITUXANHYCELA.Administer
aggressiveintravenoushydrationandanti-hyperuricemictherapyinpatientsathighriskforTLS.Correctelectrolyteabnormalities,
monitorrenalfunctionandfluidbalance,andadministersupportivecare,includingdialysisasindicated
Infections
ê Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion
oftherapywithrituximab-containingproducts,includingRITUXANHYCELA.Infectionshavebeenreportedinsomepatientswith
prolonged hypogammaglobulinemia (>11 months after rituximab exposure). Discontinue RITUXAN HYCELA for serious infections
andinstituteappropriateanti-infectivetherapy
Cardiovascular Adverse Reactions
ê Cardiacadversereactions,includingventricularfibrillation,myocardialinfarction,andcardiogenicshock,mayoccurwithrituximab-
containing products, including RITUXAN HYCELA
ê DiscontinueRITUXANHYCELAforseriousorlife-threateningcardiacarrhythmias.Performcardiacmonitoringduringandafterall
administrationsofRITUXANHYCELAforpatientswhodevelopclinicallysignificantarrhythmias,orwhohaveahistoryofarrhythmia
or angina
Renal Toxicity
ê Severe,includingfatal,renaltoxicitycanoccurafteradministrationofrituximab-containingproducts,includingRITUXANHYCELA.
Monitor closely for signs of renal failure and discontinue RITUXAN HYCELA in patients with a rising serum creatinine or oliguria